Literature DB >> 27862281

Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey.

Tao Bai1, Jing Xia1, Yudong Jiang1, Huan Cao2, Yong Zhao3, Lei Zhang1, Huan Wang1, Jun Song1, Xiaohua Hou1.   

Abstract

BACKGROUND AND AIMS: The aims of this study were to investigate the proportion of clinical irritable bowel syndrome (IBS) at a tertiary hospital in China, to compare the Rome III and Rome IV criteria with regard to IBS diagnosis, to describe the agreement between the Rome III and Rome IV criteria, and to identify differences between Rome IV-positive and -negative IBS patients.
METHODS: A cross-sectional survey was performed among outpatients in the gastrointestinal (GI) department of a tertiary hospital. The patients were categorized as having IBS using Rome III and Rome IV criteria.
RESULTS: In total, 1,376 (91.7%) patients completed a GI symptom questionnaire. Among them, 352 were suspected of having IBS and 175 were diagnosed with IBS using the Rome III or Rome IV criteria. In particular, 170 (12.4%) patients were diagnosed with IBS using the Rome III criteria, and 84 (6.1%) patients were diagnosed using the Rome IV criteria. Rome IV IBS patients experienced more pain symptoms (P<0.01) and showed higher IBS severity scores. In contrast, no significant differences were noted for demographic characteristics, stool frequency, IBS subtype, disease course, operation history or GI infection history between Rome IV IBS patients and IBS patients not diagnosed with the Rome IV criteria.
CONCLUSIONS: Rome IV-positive IBS patients represented approximately half of Rome III-positive IBS patients at a tertiary hospital in China. More specifically, Rome IV-positive IBS was mainly a subgroup of Rome III-positive IBS with more serious symptoms.
© 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Rome III criteria; Rome IV criteria; epidemiology; irritable bowel syndrome; screening and diagnosis

Mesh:

Year:  2017        PMID: 27862281     DOI: 10.1111/jgh.13642

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  29 in total

1.  Efficacy of non-pharmacological treatment for adult patients with chronic constipation.

Authors:  Maryam Soheilipour; Elham Goudarzinejad; Elham Tabesh
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-08-15

2.  Subepithelial Serotonin Reduces Small Intestinal Epithelial Cell Tightness via Reduction of Occluding Expression.

Authors:  Hideki Horie; Osamu Handa; Yuji Naito; Atsushi Majima; Yuriko Yasuda-Onozawa; Yukiko Uehara; Kazuhiro Kamada; Kazuhiro Katada; Kazuhiko Uchiyama; Takeshi Ishikawa; Tomohisa Takagi; Yoshito Itoh; Akiko Shiotani
Journal:  Turk J Gastroenterol       Date:  2022-01       Impact factor: 1.555

3.  Relationships Between Abdominal Pain and Fatigue With Psychological Distress as a Mediator in Women With Irritable Bowel Syndrome.

Authors:  Claire J Han; Monica E Jarrett; Margaret M Heitkemper
Journal:  Gastroenterol Nurs       Date:  2020 Jan/Feb       Impact factor: 1.159

Review 4.  Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal.

Authors:  Adam Fabisiak; Jakub Włodarczyk; Natalia Fabisiak; Martin Storr; Jakub Fichna
Journal:  J Neurogastroenterol Motil       Date:  2017-07-30       Impact factor: 4.924

5.  The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Tao Bai; Haoyu Zeng; Yanqin Long; Xiaoqing Li; Xiaohong Sun; Yu Lan; Lingling Gao; Lu Zhang; Zenghui Feng; Xiaohua Hou
Journal:  Trials       Date:  2020-06-30       Impact factor: 2.279

6.  Irritable bowel syndrome increases the risk of chronic obstructive pulmonary disease: A retrospective cohort study.

Authors:  Hsiang-Chun Lai; Hung-Jen Lin; Yi-Wei Kao; Kai-Hsun Wang; Jen-Wei Chou; Ben-Chang Shia; Sheng-Teng Huang
Journal:  Sci Rep       Date:  2020-06-19       Impact factor: 4.379

7.  Improved Symptom Profiles and Minimal Inflammation in IBS-D Patients Undergoing a Long-Term Low-FODMAP Diet: A Lipidomic Perspective.

Authors:  Antonella Orlando; Valeria Tutino; Maria Notarnicola; Giuseppe Riezzo; Michele Linsalata; Caterina Clemente; Laura Prospero; Manuela Martulli; Benedetta D'Attoma; Valentina De Nunzio; Francesco Russo
Journal:  Nutrients       Date:  2020-06-02       Impact factor: 5.717

Review 8.  Pros and Cons While Looking Through an Asian Window on the Rome IV Criteria for Irritable Bowel Syndrome: Pros.

Authors:  Uday C Ghoshal
Journal:  J Neurogastroenterol Motil       Date:  2017-07-30       Impact factor: 4.924

9.  Does propolis affect the quality of life and complications in subjects with irritable bowel syndrome (diagnosed with Rome IV criteria)? A study protocol of the randomized, double-blinded, placebo-controlled clinical trial.

Authors:  Mahsa Miryan; Pezhman Alavinejad; Mohammadreza Abbaspour; Davood Soleimani; Alireza Ostadrahimi
Journal:  Trials       Date:  2020-08-05       Impact factor: 2.279

10.  Interoceptive Abilities in Inflammatory Bowel Diseases and Irritable Bowel Syndrome.

Authors:  Alicia Fournier; Laurie Mondillon; Olivier Luminet; Fréderic Canini; Nicolas Mathieu; Anne Sophie Gauchez; Cécile Dantzer; Bruno Bonaz; Sonia Pellissier
Journal:  Front Psychiatry       Date:  2020-04-02       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.